Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …

Abstract Abstract 2673 Background: Romidepsin is a potent histone deacetylase inhibitor
approved by the FDA for patients with cutaneous T-cell lymphoma and PTCL who have …

This issue of JAMA Oncology reports a strategy for managing romidepsin therapy in patients
with cutaneous T-cell lymphoma (CTCL), asking, what should we do to maintain remission …

Two multicenter, single‐arm, single‐infusion, open‐label studies were conducted to
evaluate the effect of ketoconazole (a strong CYP3A inhibitor) or rifampin (a strong CYP3A …

Background: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are
independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that …

This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …

Background Histone deacetylase inhibitor romidepsin has demonstrated durable clinical
responses and tolerability in patients with relapsed/refractory peripheral and cutaneous T …

Romidepsin is a histone deacetylase inhibitor with high inhibitory activity for class I histone
deacetylases. Intravenous romidepsin is indicated in the US for the treatment of adult …

Introduction: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi).
It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a …

Abstract Abstract 114 Background: Romidepsin is a potent HDAC inhibitor approved by the
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …